SHANGHAI – High-flying CAR T developer, Kite Pharma Inc., of Santa Monica, Calif., is making a push into China and Japan. A pair of deals – Shanghai Fosun Pharmaceutical (Group) Co. Ltd. and Daiichi-Sankyo Co. Inc. – features lead asset, KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for which the company is on track to submit a BLA to the FDA later this year.